Fulgent Genetics Inc (FLGT) - Total Liabilities
Based on the latest financial reports, Fulgent Genetics Inc (FLGT) has total liabilities worth $93.24 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Fulgent Genetics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Fulgent Genetics Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Fulgent Genetics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Fulgent Genetics Inc assets under control.
Fulgent Genetics Inc Competitors by Total Liabilities
The table below lists competitors of Fulgent Genetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanxi Huhua Group Co Ltd
SHE:003002
|
China | CN¥726.24 Million |
|
CCCG Real Estate Corp Ltd
SHE:000736
|
China | CN¥1.09 Billion |
|
Triductor Technology (Suzhou) Inc.
SHG:688259
|
China | CN¥232.01 Million |
|
COOR Service Management AB
ST:COOR
|
Sweden | Skr5.73 Billion |
|
Pilani Investment and Industries Corporation Limited
NSE:PILANIINVS
|
India | Rs37.87 Billion |
|
Inner Mongolia Xinhua Distribution Group Co.Ltd.
SHG:603230
|
China | CN¥1.76 Billion |
|
Shenzhen Fluence Technology PLC
SHE:300647
|
China | CN¥1.72 Billion |
|
Zhejiang Jindun Fans Co Ltd
SHE:300411
|
China | CN¥472.48 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Fulgent Genetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See FLGT equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fulgent Genetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fulgent Genetics Inc (2014–2025)
The table below shows the annual total liabilities of Fulgent Genetics Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $106.81 Million | +17.63% |
| 2024-12-31 | $90.81 Million | -11.01% |
| 2023-12-31 | $102.04 Million | -12.17% |
| 2022-12-31 | $116.18 Million | +2.96% |
| 2021-12-31 | $112.84 Million | -13.91% |
| 2020-12-31 | $131.07 Million | +2092.24% |
| 2019-12-31 | $5.98 Million | +117.81% |
| 2018-12-31 | $2.75 Million | -6.15% |
| 2017-12-31 | $2.92 Million | -17.86% |
| 2016-12-31 | $3.56 Million | +419.10% |
| 2015-12-31 | $686.00K | +57.34% |
| 2014-12-31 | $436.00K | -- |
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more